ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR)

Historical Holders from Q4 2014 to Q3 2025

Symbol
ARWR on Nasdaq
CUSIP
04280A100
Type / Class
Equity / Common stock, par value $0.001 per share (the "Common Stock")
Shares outstanding
139M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
111M
Holdings value
$3.82B
% of all portfolios
0.003%
Grand Portfolio weight change
+0%
Number of holders
297
Number of buys
165
Number of sells
-120
Average Value change %
+0%
Average buys %
+0.001%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 13.8% $254M 19M BlackRock, Inc. Mar 31, 2025
VANGUARD GROUP INC 11.24% $245M 15.5M The Vanguard Group Jun 30, 2025
Avoro Capital Advisors LLC 8.3% -13% $193M -$8.58M 11.5M -4.25% Avoro Capital Advisors LLC Jun 30, 2025
STATE STREET CORP 4.6% -10% $107M -$10.5M 6.37M -8.98% STATE STREET CORPORATION Jun 30, 2025

Institutional Holders of ARROWHEAD PHARMACEUTICALS, INC. - Common stock, par value $0.001 per share (the "Common Stock") (ARWR)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 111M $3.82B +$262M $34.49 297
2025 Q2 106M $1.67B +$44.7M $15.80 279
2025 Q1 103M $1.32B +$23.7M $12.74 258
2024 Q4 99.7M $1.87B +$71.2M $18.80 267
2024 Q3 95.7M $1.85B -$144M $19.37 269
2024 Q2 97.8M $2.54B +$101M $25.99 272
2024 Q1 94.9M $2.71B +$493M $28.60 265
2023 Q4 77.4M $2.37B +$123M $30.60 265
2023 Q3 73.4M $1.97B +$272K $26.87 251
2023 Q2 71.8M $2.56B -$10.5M $35.66 270
2023 Q1 72.9M $1.85B -$22.2M $25.40 252
2022 Q4 73.2M $2.97B +$97.5M $40.56 278
2022 Q3 71M $2.34B -$41.9M $33.05 264
2022 Q2 72.1M $2.54B +$101M $35.21 263
2022 Q1 69.2M $3.18B +$35.9M $45.99 293
2021 Q4 67.9M $4.5B +$55.9M $66.30 299
2021 Q3 66.5M $4.15B -$66.6M $62.43 282
2021 Q2 66.9M $5.54B -$140M $82.82 307
2021 Q1 68.4M $4.54B -$29.6M $66.31 280
2020 Q4 69.4M $5.33B +$77.9M $76.73 306
2020 Q3 68.1M $2.94B -$17.5M $43.06 257
2020 Q2 68.6M $2.96B +$130M $43.19 241
2020 Q1 65.8M $1.89B -$65.6M $28.77 231
2019 Q4 64.8M $4.11B -$251M $63.43 286
2019 Q3 65.6M $1.85B -$64.1M $28.18 218
2019 Q2 68.2M $1.81B +$469M $26.50 210
2019 Q1 58.9M $1.08B +$8M $18.35 173
2018 Q4 58.6M $728M +$3.19M $12.42 158
2018 Q3 55.9M $1.07B +$87.7M $19.17 133
2018 Q2 51.7M $703M +$175M $13.60 114
2018 Q1 40.7M $293M +$131M $7.21 88
2017 Q4 23.4M $86M +$30.4M $3.68 75
2017 Q3 15M $64.9M +$4.08M $4.33 54
2017 Q2 15.4M $25M -$15.5M $1.62 54
2017 Q1 24.3M $45M +$7.66M $1.85 78
2016 Q4 25.5M $39.5M -$54.9M $1.55 79
2016 Q3 30.1M $221M +$70.4M $7.35 94
2016 Q2 20.6M $110M +$97.6M $5.32 84
2016 Q1 2.13M $10.3M +$10.3M $4.82 7
2015 Q4 500 $4K $8.00 1
2015 Q3 500 $3K $0 $6.00 1
2015 Q2 500 $4K $0 $8.00 1
2015 Q1 500 $4K $0 $8.00 1
2014 Q4 500 $4K $0 $8.00 1